First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
NCT07756281
Summary
This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.
Eligibility
Inclusion Criteria: * Adults (18 years and older). * Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. * Cancer confirmed by tissue or cell examination (histology or cytology). * At least one measurable tumor on scans. * Good enough general health and organ function to receive study treatment, as judged by the study doctor. * Able to swallow oral medicines. * Willing to follow study visit schedule and contraception requirements. Exclusion Criteria: * Serious heart, lung, liver, or other medical problems that would make study treatment unsafe. * Active, uncontrolled infections. * Other active cancers that could interfere with study assessments (except certain early-stage cancers that have been treated). * Prior treatments or medicines that are not allowed by the protocol (for example, some strong drug interactions). * Known brain or nervous system involvement from the cancer that is not stable or controlled. * Pregnant or breastfeeding, or unwilling to use required birth control during and after the study.
Conditions3
Interventions2
Locations1 site
Find trials near these locations
Related trials
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) — Revolution Medicines, Inc.
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — Revolution Medicines, Inc.
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Revolution Medicines, Inc.
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma — Revolution Medicines, Inc.
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Revolution Medicines, Inc.
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors — Revolution Medicines, Inc.
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) — Bristol-Myers Squibb
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors — Revolution Medicines, Inc.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07756281